Internal Medicine | Page 171 of 487 | Links Medicus Content Curation & Alerts in Medicine

Drug-drug interactions with direct oral anticoagulants: practical recommendations for clinicians.

10 Sep, 2021 | 04:59h | UTC

Drug-Drug Interactions with Direct Oral Anticoagulants: Practical Recommendations for Clinicians – The American Journal of Medicine

[Preprint] RCT: Additional heterologous vs. homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination.

9 Sep, 2021 | 09:55h | UTC

Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial – medRxiv

Commentary on Twitter (thread – click for more)

https://twitter.com/hildabast/status/1435720202147143680

AstraZeneca bosses warn against rush for boosters – “giving the most vulnerable, who may not have built up a full immune response from the first two, a third, top-up dose is “sensible”. But any decision to give a third, booster jab “to large swathes of the population”, to extend their protection from the first two, must be based on clinical data”.

9 Sep, 2021 | 09:59h | UTC

AstraZeneca bosses warn against rush for boosters – BBC

Commentary on Twitter (thread – click for more)

"Moving too quickly to boost across the entire adult population will deprive us of these insights, leaving this important decision to rest on limited data," Mr Soriot and Sir Mene write.https://t.co/xTAk7yyu5G

— The Sharing Scientist (@ScienceShared) September 8, 2021

A large observational study suggests eating a plant-rich diet could reduce the risk of developing severe COVID-19.

9 Sep, 2021 | 09:51h | UTC

Eating a plant rich diet reduces risk of developing COVID-19 – King’s College London

Original study: Diet quality and risk and severity of COVID-19: a prospective cohort study – Gut

RCT: A Seven-days course of antibiotics for the treatment of bloodstream infections by Enterobacterales was noninferior to a 14-days course.

9 Sep, 2021 | 09:03h | UTC

Seven versus 14-days course of antibiotics for the treatment of bloodstream infections by Enterobacterales. A randomized, controlled trial – Clinical Microbiology and Infection

Commentary on Twitter

SHORTEN RCT 🔥🔥🔥@CMIJournal
Seven versus 14-days course of antibiotics for the treatment of bloodstream infections by Enterobacterales
7-day course of antibiotics as the preferential treatment for eBSI, as long as the source is properly controlled https://t.co/pyaOMl52us pic.twitter.com/wK1sgeMe36

— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) September 8, 2021

Editorial | Anticholinergic drugs and dementia: time for transparency in the face of uncertainty.

9 Sep, 2021 | 08:57h | UTC

Anticholinergic drugs and dementia: time for transparency in the face of uncertainty – Cochrane Library

Systematic review: Anticholinergic burden (prognostic factor) for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome – Cochrane Library

Commentary on Twitter

Anticholinergic drugs may double the risk of developing dementia. What should we be doing right now?
Editorial with @JenMStevenson for @CochraneLibrary published todayhttps://t.co/808wSGPUtm

— Henry Woodford (@woodford_henry) September 8, 2021

Perspective | Rethinking medication adherence.

9 Sep, 2021 | 08:55h | UTC

Rethinking Medication Adherence – Therapeutics Initiative

Review: Heart failure with mid-range or mildly reduced ejection fraction.

9 Sep, 2021 | 08:52h | UTC

Heart failure with mid-range or mildly reduced ejection fraction – Nature Reviews Cardiology (free for a limited period)

Commentary on Twitter

In a new Review, Lars Lund et al. discuss the epidemiology, clinical profile, prognosis and potential treatment of patients with #HeartFailure with mid-range or mildly reduced ejection fraction (HFmrEF) https://t.co/npDGByESCj pic.twitter.com/dWcRZLJGHW

— Nature Reviews Cardiology (@NatRevCardiol) September 8, 2021

Spread of Delta SARS-CoV-2 variant driven by a combination of immune escape and increased infectivity.

7 Sep, 2021 | 21:49h | UTC

News release: Spread of Delta SARS-CoV-2 variant driven by combination of immune escape and increased infectivity – University of Cambridge

Original article: SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion – Nature

Radiation‐induced cardiovascular disease: review of an underrecognized pathology.

9 Sep, 2021 | 08:54h | UTC

Radiation‐Induced Cardiovascular Disease: Review of an Underrecognized Pathology – Journal of the American Heart Association

Cochrane review: evidence is insufficient to draw meaningful conclusions if SARS‐CoV‐2-specific monoclonal antibodies are effective in the treatment of COVID-19.

7 Sep, 2021 | 21:51h | UTC

Summary: Are laboratory-made, COVID-19-specific monoclonal antibodies an effective treatment for COVID-19? – Cochrane Library

Original review: SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 – Cochrane Library

Recent cannabis use linked to increased risk of myocardial infarction in young adults: a cross-sectional study.

7 Sep, 2021 | 21:38h | UTC

Recent cannabis use and myocardial infarction in young adults: a cross-sectional study – Canadian Medical Association Journal

News release: Recent cannabis use linked to heart attack risk in younger adults – Canadian Medical Association Journal

Commentary: Young adult cannabis consumers nearly twice as likely to suffer from a heart attack, research shows – CNN

[Preprint] M-A of 12.011.447 individuals finds individuals previously infected with SARS-CoV-2 had an 81% reduction in odds of a reinfection.

7 Sep, 2021 | 21:42h | UTC

The prevalence of adaptive immunity to COVID-19 and reinfection after recovery, a comprehensive systematic review and meta-analysis of 12 011 447 individuals – medRxiv

Commentary on Twitter

A new systematic review of over 12 million people from 54 studies at up to 8 months following Covid. >90% prevalence of IgG antibodies, reinfection 0.2% (an 81% risk reduction) https://t.co/ljir4DV1zU ("did not examine evidence for immunity against the new variants") pic.twitter.com/pT7A2KA9FV

— Eric Topol (@EricTopol) September 7, 2021

Supplement: Current Issues in Venous Thromboembolism.

7 Sep, 2021 | 21:36h | UTC

Homepage: Current Issues in Venous Thromboembolism – Postgraduate Medicine

Editorial: Current issues in venous thromboembolism

A review of upper extremity deep vein thrombosis

Outpatient treatment of emergency department patients diagnosed with venous thromboembolism

Venous thromboembolism prophylaxis in high-risk orthopedic and cancer surgery

Prophylaxis and treatment of COVID-19 related venous thromboembolism

Challenges in the diagnostic approach of suspected pulmonary embolism in COVID-19 patients

Catheter-directed thrombolysis and mechanical intervention in deep venous thrombosis: what is the status after the ATTRACT trial?

Post-hospital discharge venous thromboembolism prophylaxis in medically ill patients

Radiologic mimics of pulmonary embolism

A comprehensive review of DOACs for cancer associated VTE prophylaxis or treatment

The Lancet Series: Interstitial Lung Disease 2021.

7 Sep, 2021 | 21:37h | UTC

Homepage: Interstitial Lung Disease 2021 (free registration required for all articles)

Disease pathology in fibrotic interstitial lung disease: is it all about usual interstitial pneumonia?

Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities

Treatment of fibrotic interstitial lung disease: current approaches and future directions

Interstitial lung diseases: quo vadis?

Moving beyond usual interstitial pneumonia to define progressive fibrotic interstitial lung disease

Commentary on Twitter (thread – click for more)

🆕 The term interstitial lung disease (ILD) refers to a diverse group of inflammatory & fibrotic conditions—with fibrotic ILD being a disease subset that constitutes a major global health problem.

Read the new @TheLancet & @LancetRespirMed Series. https://t.co/zV2Vw2l4rV pic.twitter.com/AqAe4GUlmr

— The Lancet (@TheLancet) September 7, 2021

Extended intervals and extra doses of the AstraZeneca vaccine are associated with increased immunogenicity.

7 Sep, 2021 | 10:56h | UTC

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) – The Lancet

Invited commentary: Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine

Commentaries on Twitter

(thread – click for more)

Substudy suggests extended interval (up to 45 wks) before 2nd dose of ChAdOx1 nCoV-19 leads to increased antibody titres, offering more flexibility in vaccine schedules.

Extended interval before 3rd dose resulted in further increase in immune responses. https://t.co/J3xOwSSYMN pic.twitter.com/8GotDI4ctS

— The Lancet (@TheLancet) September 2, 2021

(thread – click for more)

New @TheLancet
The heightened immune response to longer spacing @AstraZeneca 1st -> 2nd vaccine doses and the response 3rd booster dose, with high neutralizing antibodies and T cellshttps://t.co/A2UcPVIFYP pic.twitter.com/zfYaW0T8Yf

— Eric Topol (@EricTopol) September 1, 2021

Opinion | Liquid biopsy: misplaced faith in early cancer detection?

7 Sep, 2021 | 21:30h | UTC

Liquid biopsy: misplaced faith in early cancer detection? – STAT

Commentary on Twitter

Opinion: "The real money isn’t in testing the relatively few people with advanced cancer, it’s in testing everyone else: those not known to have cancer." Screening liquid biopsies could become standard care before we know if they save lives https://t.co/1IAo5Kb0vm via @statnews

— Gideon Gil (@GideonGil) August 31, 2021